Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Myeloid Leukemia (AML)
- B-cell Acute Lymphoblastic Leukemia (b-ALL)
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: Dose escalation follows an adaptive design.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04230265
- Collaborators
- PHARMALOG Institut für klinische Forschung GmbH
- Investigators
- Principal Investigator: Martin Wermke, MD Universitätsklinikum Carl Gustav Carus Dresden
Get Well Soon